Lessons learned from the COVID-19 pandemic about sample access for research in the UK.
Lessons learned from the COVID-19 pandemic about sample access for research in the UK.
复制标题
DOI：
10.1136/bmjopen-2020-047309
复制
发表时间：
2022-04-15
期刊：
影响因子：
2.9
通讯作者：
Quinlan, Philip R.
中科院分区：
文献类型：
--
作者：
Sims, Jessica M.;Lawrence, Emma;Glazer, Katy;Gander, Amir;Fuller, Barry;Davidson, Brian R.;Garibaldi, Jonathan;Quinlan, Philip R.
从患者身上提取的带注释的临床样本是转化医学研究的基础，并提供了对药物试验的机械性见解。组织目录和协调中心(TDCC)之前的研究表明，研究人员，特别是工业界的研究人员，在获取患者样本方面面临许多障碍。新冠肺炎疫情抵达英国后，立即产生了极端的冲击波，对开展所有关键翻译研究的能力造成了影响。作为国家协调中心，TDCC的任务是提高生物库部门的效率。因此，我们负责确定和协调能够在2020年3月至9月期间为研究人员收集新冠肺炎相关样本的英国组织样本收集组织(生物库)。在英国新冠肺炎疫情的第一波期间，近三分之一的英国生物库被关闭。在其余的人中，43%的人能力有限，26%的人保持正常活动。在全国重点开展的新冠肺炎干预性研究中，5项回复问题的研究中只有3项采集了人体样本。在TDCC收到的41份新冠肺炎样品请求中，由于缺乏英国的协调战略，只有4份能够得到满足。与此同时，在幕后有大量报道称，英国的样本收集在很大程度上仍未得到充分利用。对大流行的应对需要高水平的协调研究反应，以降低死亡率。我们的研究突显了英国各地人类样本收集和临床试验之间缺乏效率和协调。英国的样本访问对研究人员、临床医生或患者都不起作用。需要彻底改变样本收集和分发的战略，以最大限度地利用这一宝贵的人类捐赠样本资源。
Annotated clinical samples taken from patients are a foundation of translational medical research and give mechanistic insight into drug trials. Prior research by the Tissue Directory and Coordination Centre (TDCC) indicated that researchers, particularly those in industry, face many barriers in accessing patient samples. The arrival of the COVID-19 pandemic to the UK produced an immediate and extreme shockwave, which impacted on the ability to undertake all crucial translational research. As a national coordination centre, the TDCC is tasked with improving efficiency in the biobanking sector. Thus, we took responsibility to identify and coordinate UK tissue sample collection organisations (biobanks) able to collect COVID-19-related samples for researchers between March and September 2020. Almost a third of UK biobanks were closed during the first wave of the UK COVID-19 pandemic. Of the remainder, 43% had limited capabilities while 26% maintained normal activity. Of the nationally prioritised COVID-19 interventional studies, just three of the five that responded to questioning were collecting human samples. Of the 41 requests for COVID-19 samples received by the TDCC, only four could be fulfilled due to a lack of UK coordinated strategy. Meanwhile, in the background there are numerous reports that sample collections in the UK remain largely underutilised. The response to a pandemic demands high level co-ordinated research responses to reduce mortality. Our study highlights the lack of efficiency and coordination between human sample collections and clinical trials across the UK. UK sample access is not working for researchers, clinicians or patients. A radical change is required in the strategy for sample collection and distribution to maximise this valuable resource of human-donated samples.
影响因子：
1.6
作者：
Lawrence, Emma;Sims, Jessica;Quinlan, Philip R.
通讯作者：
Quinlan, Philip R.